Through the Hospital Market Study carried out by IQVIA, it is observed how the offer of treatments to combat immune-mediated inflammatory diseases (IMID) grows, within a clearly expansive market and driven by biological therapies (AIB) either reference or biosimilar .
recently published
Horizon scanning
Jan 31 2024
Early Treatment: the role of biosimilars
18 2023 December
